TM , /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: ), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in , is live on the SOPHiA DDMTM Platform. The company will use SOPHiA GENETICS' technology to enhance its solid tumor testing capabilities. Dhiti Omics specializes in molecular diagnostic and genetic testing.

By implementing SOPHiA DDMTM for the Agilent SureSelect Cancer CGP application, Dhiti Omics will improve its ability to provide researchers actionable information on mutations and biomarkers across hundreds of genes. "Our team at Dhiti Omics is passionate about furthering the use of precision medicine and ensuring people in and throughout the world have access to testing for better health outcomes," said , Ph.D.

, Founder and Director of Dhiti Omics Technologies. "Combining high-quality reagents, and powerful analytics into one unique workflow will help us maximize insights from comprehensive genomic profiling data. This will ensure we're delivering the fastest and most accurate diagnostics to our customer base.

" SOPHiA DDMTM for SureSelect CGP application combines Agilent's best-in-class genomic profiling assay kit with the SOPHiA DDMTM Platform. Launched in 2023, SureSelect Cancer CGP application offers comprehensive genomic profiling. With the SOPHiA DDMTM AI Platform, Dhiti Omics will have an integrated solution for rapid and accurate.